403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Microbix Biosystems Inc.
(MENAFN- Baystreet) 10:22 AM EST - Microbix Biosystems Inc.: Announces the commercial usage of its first recombinant antigen product, the nucleocapsid protein of the SARS-CoV-2 virus (COVID-19), in its quality assessment products and its availability at commercial scale for test manufacturers. Microbix Biosystems Inc.
shares T are trading unchanged at $0.25.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment